Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

fosaprepitant

Known as: Fosaprepitantum 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
This phase III trial demonstrated that adding a single dose of fosaprepitant to a 5-HT3 receptor antagonist and corticosteroid in… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND We examined the efficacy of olanzapine for the prevention of nausea and vomiting in patients receiving highly… Expand
  • figure 1
  • figure 2
  • table 1
Is this relevant?
2015
2015
INTRODUCTION The oral neurokinin-1 antagonist aprepitant is recommended in several guidelines for preventing chemotherapy-induced… Expand
Is this relevant?
2013
2013
BACKGROUND We evaluated the efficacy and safety of single-dose fosaprepitant in combination with intravenous granisetron and… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2012
Review
2012
  • Barbara Todaro
  • Journal of the National Comprehensive Cancer…
  • 2012
  • Corpus ID: 23100176
Before the introduction of the serotonin receptor antagonists (5-HT3 receptor antagonists) in the early 1990s, limited effective… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an ondansetron and dexamethasone regimen improves… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
ASCO's update to its antiemetics guideline now includes an evaluation of evidence on complementary antiemetic therapy. 
  • table 1
  • table 1
  • table 3
  • table 2
  • table 4
Is this relevant?
2011
2011
Aprepitant or its prodrug fosaprepitant, in combination with a corticosteroid and a 5-HT(3) receptor antagonist, are used to… Expand
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Fosaprepitant is an intravenous formulation of aprepitant, an oral NK1 antagonist used to prevent chemotherapy-induced nausea and… Expand
  • table I
  • table II
  • table III
  • table IV
  • table V
Is this relevant?
Review
2007
Review
2007
Chemotherapy-induced nausea and vomiting (CINV) is a distressing and common adverse event associated with cancer treatment… Expand
Is this relevant?